 |
|
|
 |
Mice, Flies Further Implicate Retromer in AD Pathogenesis
12 May 2008. Consider a study in last week’s online PNAS a reminder that one lab’s trash could be another’s treasure...
|
| |
|
More Precious Than Gold? Platinum Inhibitors Target Aβ
9 May 2008. A new approach to detoxifying the amyloid-β (Aβ) peptide borrows from an unlikely source—the field of cancer drugs...
|
| |
|
Changes In Cortical Thickness Mirror Loss of Network Connectivity in AD
8 May 2008. The arrangement of linked brain regions into functional networks supports complex mental activity...
|
| |
GO TO ALL RESEARCH NEWS  |
|
|
 |
|
|
In the spotlight
|
 |
Senate Hearing on Alzheimer’s Available Online
|
 |
On 14 May, eFAD advocate Chuck Jackson, retired Justice of the U.S. Supreme Court Sandra Day O’Connor, MGH geneticist Rudy Tanzi, and others testified before the U.S. Senate. Herb Kohl (D-Wisc), who chairs the Senate Special Committee on Aging, led a hearing called “The Future of Alzheimer's: Breakthroughs and Challenges." The hearing and its written testimony are available online. They are part of a public policy initiative on Alzheimer disease held in conjunction with the work of the Alzheimer Study Group and the Alzheimer Association's 20th Annual Public Policy Forum. Jackson's story is featured in a recent Washington Post story, as is video testimony from others with early-onset AD from a recent town hall event in Washington, D.C.
|
|
|
|
|
Image of the Week: SLICK Neurons in Mouse Cortex
|
|
|
|
|
|
A new method called Single-neuron Labeling with Inducible Cre-mediated Knockout, or SLICK for short, labels neurons with yellow fluorescent protein (YFP) while at the same time rendering them susceptible to conditional knockout of any gene. This slice of cortex from the SLICK-X mouse line shows that a subset of cortical neurons express YFP (which is actually green). The green neurons also express a Cre recombinase -estrogen receptor chimera. When crossed to any conditional knockout mice with a flox-flanked gene, knockout will happen only in green neurons and |
|
not until the mice are fed the estrogen receptor ligand tamoxifen. The labeling of these genetically manipulated neurons with YFP makes it possible to study the morphology and the dynamics of structural plasticity in the brain. Any ideas for how this could be used to study neurodegeneration? Write a comment!
|
|
|
|
Time to Envision Preventive Immunotherapy?
|
|
|
|
|
|
A new study shows that a DNA-based, anti-Aβ vaccine protects AD transgenic mice that don't yet show AD pathology. The new vaccine represents a paradigm shift in the field, where all vaccines that have reached human testing thus far have been peptide-based and geared at treating mild to moderate AD. Looking beyond the published work, lead investigator Michael Agadjanyan proposes a novel preventive AD immunotherapy strategy with a vaccine that would deploy help from memory T cells developed in response to previous shots against common bugs such as tetanus, pertussis, the flu. Given |
|
clinical setbacks of peptide-based treatment vaccines, is it time to consider prophylaxis and DNA vaccines as alternative research opportunities? Take on board Esther Landhuis's news story, a technical dialog about it, and Agadjanyan's comment on related AN1792 data, and ponder his future vaccination scheme. Then join the discussion—we cordially invite community feedback.
|
|
|
|
Alzheimer Disease Research—How to Move Forward?
|
|
Our Centennial series invited the field to train its eyes firmly on the future. We'd like to continue to solicit your sage advice—and wild ideas—for future directions in Alzheimer disease research. To this end, Alzforum scientific advisers past and present have helped us compile a summary table of ”What We Know/What We Don’t Know.” It’s a fresh and easy-to-use format to debate and discuss what the field has achieved and the most urgent priorities for future progress. |
|
|
|
|
| |
|
| |
What's New
|
|
Comments - Posted 15 May 2008
Read remarks by Kevin Barnham about Barnham KJ et al.
PAPER: Platinum-based inhibitors of amyloid-{beta} as therapeutic agents for Alzheimer's disease. |
| |
|
Job - Posted 15 May 2008
Research Scientists: Columbia University, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, New York, NY. |
| |
|
Comments - Posted 14 May 2008
Read remarks by Corinne Augelli-Szafran about
Barnham KJ et al.
NEWS: More Precious Than Gold? Platinum Inhibitors Target Aβ |
| |
|
Comments - Posted 14 May 2008
Read remarks by Gordon Wilcock about Wilcock GK et al.
PAPER: Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. |
| |
|
Comments - Posted 14 May 2008
Read remarks by Emory Hill
Alzforum: News: AD Vaccine |
| |
|
Comments - Posted 14 May 2008
Read remarks by M. Paul Murphy
Alzforum: News: AD Vaccine |
| |
|
Comments - Posted 13 May 2008
Read remarks by Boris Schmidt about Barnham KJ et al.
PAPER: Platinum-based inhibitors of amyloid-{beta} as therapeutic agents for Alzheimer's disease. |
| |
|
Comments - Posted 13 May 2008
Read remarks by Kevin Barnham about Barnham KJ et al.
PAPER: Platinum-based inhibitors of amyloid-{beta} as therapeutic agents for Alzheimer's disease. |
SEE MORE |
|
|
|
|
Home
